1.小分子靶向抗肿瘤药物研发及机制研究
2.放疗增敏剂的筛选及活性评价
3.放化疗保护剂研发及机制研究

1. Guoquan Wan, Zhanzhan Feng, Qiangsheng Zhang, Xiao Li, Kai Ran, Huan Feng, Tianwen Luo, Shuyan Zhou, Chang Su, Wei Wei, Ningyu Wang, Chao Gao, Lifeng Zhao,* and Luoting Yu, Design and Synthesis of Fibroblast Growth Factor Receptor (FGFR) and Histone Deacetylase (HDAC) Dual Inhibitors for the Treatment of Cancer, J. Med. Chem, 2022, 65(24):16541-16569.(IF:8.039)
2. Chaoguo Cao, Jie Yang, Yong Chen, Peiting Zhou, Yingwei Wang, Wu Du, Lifeng Zhao,*and Yuanwei Chen, Discovery of SK-575 as a Highly Potent and Efficacious Proteolysis-Targeting Chimera Degrader of PARP1 for Treating Cancers. J. Med. Chem, 2020, 63(19): 11012-11033. (IF:8.039)
3. Zhan Miao, Deng Yu, Lifeng Zhao*,Guoyi Yan, Fangying Wang, Ye Tian, Lanxi Zhang, Hongxia Jiang, and Yuanwei Chen, Design, synthesis, and biological evaluation of dimorpholine substituted thienopyrimidines as potential class I PI3K/mTOR dual inhibitors. J. Med. Chem, 2017, 60, 9: 4023-4035. (IF:8.039)
4. Lidan Zhang; Wen Ren; Xiaoyan Wang; Jiaying Zhang; Jie Liu; Lifeng Zhao*; Xia Zhang; Discovery of novel polycyclic spiro-fused carbocyclicoxindole-based anticancer agents, Eur J Med Chem, 2017, 126: 1071-1082. (IF: 7.088)
5. Fangying Wang , Zhuoling Li , Tao Zhang, Guoyi Yan, Mingxing Hu, Lifeng Zhao*, Yinglan Zhao, Yuanwei Chen. Discovery of a novel class of pyridine derivatives that selectively inhibits mutant Isocitrate dehydrogenase 2. Chem Biol Drug Des, 2017. (IF:2.548)
6. Yingwei Wang, Yufang Deng, Xuehai Pang, Jiang Yu, Lei Fan, Yuanwei Chen and Lifeng Zhao*, Novel thiohydantoin analogues bearing the 1-hydroxyl-2, 2, 2-trifluoro-1-ethyl moiety as androgen receptor inhibitors for the potential treatment of castration resistant prostate cancer. RSC Advances, 2017, 7,51: 31866-31874. (IF: 4.036)
7. Tinghong Ye; Shirui Zhu; Yongxia Zhu; Qiang Feng; Bing He; Yiong Xiong; Lifeng Zhao*; Yiwen Zhang, Luoting Yu; Li Yang; Cryptotanshinone induces melanoma cancer cells apoptosis via ROS-mitochondrial apoptotic pathway and impairs cell migration and invasion, Biomed. Pharmacother., 2016, 82: 319-326.(IF: 7.419)
8. Hong-bao Sun, Xiao-yan Wang, Guo-bo Li,a Li-dan Zhang, Jie Liu and Li-feng Zhao*, Design, synthesis and biological evaluation of novel C3-functionalized oxindoles as potential Pim-1 kinase inhibitors, RSC Advances., 2015, 5, 29456–29466. (IF: 4.036)
9. Ruixue Xu; Miao Zhan; Lingling Peng; Xuehai Pang; Jun Yang; Tao Zhang; Hongxia Jiang; Lifeng Zhao*; Yuanwei Chen∗；Design, synthesis and biological evaluation of deuterated nintedanib for improving pharmacokinetic properties, J Labelled Comp Radiopharm, 2015, 58(7): 308-312.(IF: 1.949)
10. Hong-bao Sun; Xiao-yan Wang; Guo-bo Li; Li-dan Zhang; Jie Liu; Li-feng Zhao*; Design, synthesis and biological evaluation of novel C3-functionalized oxindoles as potential Pim-1 kinase inhibitors, RSC Advances, 2015, 5: 29456–29466.(IF: 4.036)
11. Zhao Lifeng; Li Xiao; Zhang Lidan; Ye Tinghong; Zhu Yongxia; Wei Yuquan; Yang Shengyong; Yu Luoting*, Novel small molecules as apoptosis inducers: synthesis preliminary structure-activity relationships and in vitro biological evaluation, Bioorg. Med. Chem. Lett.，2013, 23: 2293-2297.(IF: 2.940)
12. Lifeng Zhao, Dejun Fei, Yagu Dang, Xiaolong Zhou, Jiali Xiao. Studies on the extraction of chromium(III) by emulsion liquid membrane, J. Hazard. Mater, 2010, 178(1–3): 130-135. (IF:10.588)

纵向课题：
1.主持四川省科技厅应用基础项目，《新型EZH2抑制剂的优化合成及对去势抵抗性前列腺癌转移的机制研究》，19YYJC0761，2019-2021。
2.主持成都市科技局产业集群项目，《新型PI3K/mTOR双靶点抑制剂设计、合成及活性评价》，2016-XT00-00024-GX，2016-2019。
3.主持四川省科技支撑计划项目，《1.1类靶向抗肿瘤新药的开发》，2014SZ0118-SCDX，2014-2017。
授权专利：
1. 嘌呤系列衍生物及其制备方法和用途。2021，中国专利ZL201811205782.7
2. 吲哚酮衍生物及其制药用途，2022，中国专利ZL202011467844.9
3. 具有抗癌作用的氘代嘧啶衍生物，2022，中国专利ZL201910002647.0